

Please type a plus sign (+) inside this box →

+

PTO/SB/08A (10-95)
Approved for use through 10/31/99. OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

1 of 4

Complete if Known

Application Number	10/616,500
Filing Date	July 10, 2003
First Named Inventor	DALTON, James T.
Group Art Unit	Not yet known 62
Examiner Name	Not yet known S. Kumar
Attorney Docket Number	P-5234-US1

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code ² (if known)			
SK	A	10/298,229		Miller et al.	* 11-28-2002	
	B	10/270,232		Dalton et al.	* 10-15-2002	
	C	10/277,108		Dalton et al.	* 10-23-2002	
	D	10/270,233		Dalton et al.	* 10-15-2002	
	E	10/270,732		Dalton et al.	* 10-15-2002	
SK	F	10/371,213		Dalton et al.	* 02-24-2003	
	G	10/371,155		Dalton et al.	* 02-24-2003	
	H	10/371,209		Dalton et al.	* 02-24-2003	
	I	10/371,210		Dalton et al.	* 02-24-2003	
	J	10/359,270		Steiner et al.	* 02-06-2003	
SK	K	10/310,150		Steiner et al.	* 12-05-2002	
	L	6,160,011		Miller et al.	12-12-2000	
	M	6,071,957		Miller et al.	06-06-2000	
	N	6,482,861		Miller et al.	11-19-2002	
	O	6,019,957		Miller et al.	02-01-2000	
SK	P	6,492,554		Dalton et al.	12-10-2002	
	Q	6,569,896		Dalton et al.	05-27-2003	
SK	R	4,636,505		Tucker	01-13-1987	
	S	4,880,839		Tucker	11-14-1989	
	T	4,465,507		Konno, et al.	08-14-1984	
	U	3,875,229		Gold	04-01-1975	
	V	4,139,638		Neri, et al.	02-13-1979	
	W	4,191,775		Glen	03-04-1980	
	X	4,239,776		Glen, et al.	12-16-1980	
	Y	4,386,080		Crossley, et al.	05-31-1983	
	Z	4,282,218		Glen, et al.	08-14-1981	
	AA	5,609,849		Kung	03-11-1997	
	AB	5,162,504		Horoszewicz	11-10-1992	
	AC	5,656,651		Sovak, et al.	08-12-1997	

Examiner
Signature

S. Kumar

Date
Considered

7/29/05

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside the box → ☐

MAR 08 2004

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

PTO/SB/08A (10-86)

Approved for use through 10/31/99. OMB 0651-0031

Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

<p>Substitute for form 1449B/PTO</p> <p>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</p> <p>(use as many sheets as necessary)</p>		Complete if Known	
		Application Number	10/616,500
		Filing Date	July 10, 2003
		First Named Inventor	DALTON, James T.
		Group Art Unit	Not yet known 162
		Examiner Name	Not yet known S. Kumar
Attorney Docket Number	P-5234-US1		
Sheet	2	of	4

U.S. PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code ² (if known)			


FOREIGN PATENT DOCUMENTS							
Examiner Initials*	Cite No. ¹	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Office ³	Number ⁴	Kind Code ⁵ (if known)			
SK	AD	WO	02 00617		Bristol-Myers Squibb	01-03-2002	
	AE	WO	01 27622		Bristol-Myers Squibb	04-19-2001	
	AF	WO	01 28990		Nobex Corporation	04-26-2001	
	AG	WO	01 34563		Nobex Corporation	05-17-2001	
	AH	WO	03 011302		Merck & Co.	02-13-2003	
	AI	WO	98 05962		Panvera Corporation	02-12-1998	
	AJ	WO	98/53826		U. of Tennessee	12-3-1998	
	AK	EP	0 100 172		Imperial Chemical Indust.	2-8-1984	
	AL	EP	0 040 932		Imperial Chemical Indust.	12-2-1981	
	AM	WO	95/19770		Sepracor Inc.	7-27-1995	
	AN	EP	0 253 503		Tucker	1-20-1988	
	AO	EP	000 2892		Imperial Chemical Indust.	2-6-1985	
	AP	JP	52-128329	Abst	Teikoku Hormone Mfg.	10-27-1977	
	AQ	JP	54-63047	Abst	Glen et al.	12-16-1980	
cl	AR	GB	1360001		Neri et al.	3-16-1970	
cl	AS	WO	02/016310		Dalton et al.	02-28-2002	
cl	AT	WO	98/55153		Dalton et al.	12-10-1998	

Examiner Signature	S. Kumar	Date Considered	7/29/05
--------------------	----------	-----------------	---------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 18 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burdan Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



PTO/SB/08A (10-95)
Approved for use through 10/31/99. OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Substitute for form 1449B/PTO		Complete If Known	
		Application Number	10/616,500
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Filing Date	July 10, 2003
		First Named Inventor	DALTON, James T.
		Group Art Unit	Not yet known 1621
		Examiner Name	Not yet known S. Kumar
Sheet	3 of 4	Attorney Docket Number	P-5234-US1

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (where appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
SE	AU	Eliason et al., "High Throughput Fluorescence Polarization-Based Screening Assays for the Identification of Novel Nuclear Receptor Ligands," Abstracts of Papers, 223rd ACS National Meeting, Orlando, FL, United States, (2002), April 7, 2002	
	AV	Howard Tucker and Glynne J. Chesterson, J. Med Chem. 1988, 31, pp. 885-887, "Resolution of the Nonsteroidal Antiandrogen - 4'-Cyano-3-[(4-fluorophenyl)sulfonyl]-2-hydroxy-2-methyl-3'-(trifluoromethyl)-propionanilide and the Determination of the Absolute Configuration of the Active Enantiomer "	
	AW	D. McKillop, et al., "Enantioselective metabolism and pharmacokinetics of Casodex in the male rat", Xenobiotica, 1995, Vol. 25, No. 6, 623-634.	
	AX	Leonid Kirkovsky, et al., "[¹²⁵ I]-Radionated Bicalutamide Analogs as Potential Imaging Agents for Prostate Cancer", Poster Presentation MEDI 155, 214th ACS National Meeting, Las Vegas, NV, Sept. 7-11, 1997, Department of Pharmaceutical Sciences, University of Tennessee, Memphis, TN 38163	
	AY	David T. Baird and Anna F. Glasier, "Hormonal Contraception - Drug Therapy", The New England Journal of Medicine, May 27, 1993, pp. 1543 - 1549	
	AZ	F.C. W. Wu, "Male Contraception: Current Status and Future Prospects", Clinical Endocrinology, (1988), 29, pp. 443-465	
	BA	Carl Djerassi and S.P. Leibe, "A new look at male contraception", Nature, Vol. 370, pp. 11-12	
	BB	World Health Organisation Task Force on Methods for the Regulation of Male Fertility, "Contraceptive efficacy of testosterone-induced azoospermia in normal men", The Lancet, Vol. 336, October 20, 1990, pp. 955-959 and 1517-1518	
	BC	C. G. Francisco, et al., "Long-acting contraceptive agents: testosterone esters of unsaturated acids", Steroids, January 1990, vol. 55, Butterworths	
	BD	John M. Hoberman and Charles E. Yesalis, "The History of Synthetic Testosterone", Scientific American, February 1995, pp. 76-81.	
	BE	Leonid Kirkovsky, et al., "Approaches to Irreversible non-steroidal chiral antiandrogens", Department of Pharmaceutical Sciences, University of Tennessee, 47th Southeast/51st Southwest Joint Regional Meeting of the American Chemical Society, Memphis, TN, Nov. 29-Dec. 1, 1995	
	BF	David J. Handelsman, "Bridging the gender gap in contraception: another hurdle cleared" The Medical Journal of Australia, Vol. 154, February 18, 1996, pp. 230-233.	


Examiner Signature	S. Kumar	Date Considered	7/29/05
--------------------	----------	-----------------	---------

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box → +



Approved for use through 10/31/99. OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Substitute for Form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Complete if Known	
		Application Number	10/616,500
		Filing Date	July 10, 2003
		First Named Inventor	DALTON, James T.
		Group Art Unit	Not yet known 1621
		Examiner Name	Not yet known S. Kumar
		Attorney Docket Number	P-5234-US1
Sheet	4	of	4

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Citation	T ²
<div style="font-size: 2em;">S</div> <div style="font-size: 2em;">K</div>	BG	Edwards JP, Higuchi RI, Winn DT, Pooley CLF, Caferro TR, Hamann LG, Zhi L, Marschke KB, Goldman ME, and Jones TK. Nonsteroidal androgen receptor agonists based on 4-(trifluoromethyl)-2H-pyrano[3,2-g]quinolin-2-one. Bioorg. Med. Chem. Lett., 9: 1003, 1999.	
	BH	Zhi L, Tegley CM, Marschke KB, and Jones TK. Switching androgen receptor antagonists to agonists by modifying C-ring substituents on piperidino[3,2-g]quinolone. Bioorg. Med. Chem. Lett., 9: 1009, 1999.	
	BI	Higuchi RI, Edwards JP, Caferro TR, Ringgenberg JD, Kong JW, Hamann LG, Arienti KL, Marschke KB, Davis RL, Farmer LJ, and Jones TK. 4-Alkyl- and 3,4-diakyl-1,2,3,4-tetrahydro-8-pyridono[5,6-g]quinolines: potent, nonsteroidal androgen receptor agonists. Bioorg. Med. Chem. Lett., 9:1335, 1999.	
	BJ	Hamann LG, Mani NS, Davis RL, Wang XN, Marschke KB, and Jones TK. Discovery of a potent, orally active nonsteroidal androgen receptor agonist: 4-ethyl-1,2,3,4-tetrahydro-6-(trifluoromethyl)-8-pyridono[5,6-g]-quinoline (LG121071). J. Med. Chem., 42: 210, 1999.	
	BK	Rosen J, Day A, Jones TK, Jones ET, Nadzan AM, and Stein RB. Intracellular receptors and signal transducers and activators of transcription superfamilies: novel targets for small-molecule drug discovery. J. Med. Chem., 38: 4855, 1995.	
	BL	Dalton JT, Mukherjee A, Zhu Z, Kirkovsky L, and Miller DD. Discovery of Nonsteroidal Androgens. Biochem. Biophys. Res. Commun., 244(1):1-4, 1998.	
	BM	Edwards JP, West SJ, Pooley CLF, Marschke KB, Farmer LJ, and Jones TK. New nonsteroidal androgen receptor modulators based on 4-(trifluoromethyl)-2-(1H)-Pyrololidino[3,2-g]quinolone. Bioorg. Med. Chem. Lett., 8: 745, 1998.	
BN	Berger et al., "Concepts and limitations in the application of radiolabeled antiandrogens, estrogens, or androgens as isotropic scanning agents for the prostate", Invest. Urol., (1975), 1391, 10-16		

Examiner Signature	<div style="font-size: 1.5em;">S. Kumar</div>	Date Considered	<div style="font-size: 1.5em;">7/29/05</div>
--------------------	-----------------------------------------------	-----------------	----------------------------------------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.